Cargando…

Immunization associated with primary tumor growth leads to rejection of commonly used syngeneic tumors upon tumor rechallenge

The recent success of multiple immunomodulating drugs in oncology highlights the potential of relieving immunosuppression by directly engaging the immune system in the tumor bed to target cancer cells. Durable responses to immune checkpoint inhibitors experienced by some patients may be indicative o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alicke, Bruno, Totpal, Klara, Schartner, Jill M, Berkley, Amy M, Lehar, Sophie M, Capietto, Aude-Hélène, Cubas, Rafael A, Gould, Stephen E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368499/ https://www.ncbi.nlm.nih.gov/pubmed/32675310 http://dx.doi.org/10.1136/jitc-2020-000532

Ejemplares similares

Peroxynitrite promotes immune evasion by reducing tumor antigenicity
por: Capietto, Aude-Hélène, et al.
Publicado: (2022)

Sequential T Cell Response Involved in Tumor Rejection of Sarcoma, Meth A, in Syngeneic Mice
por: Jiao, Yan, et al.
Publicado: (1998)

Mechanisms of syngeneic tumor rejection. Susceptibility of host- selected progressor variants to various immunological effector cells
Publicado: (1982)

The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice
Publicado: (1991)

Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
por: Zhong, Wenyan, et al.
Publicado: (2020)

Ly phenotype of cytotoxic T cells for syngeneic tumor
Publicado: (1976)

Antibody-mediated suppression of grafted lymphoma. IV. Influence of time of tumor residency in vivo and tumor size upon the effectiveness of suppression by syngeneic antibody
Publicado: (1976)

TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response
por: Zeng, Zexian, et al.
Publicado: (2021)

Regulation of cytotoxic T-cell reactivity to syngeneic tumors by the thymus
Publicado: (1978)

Tumor-localized catalases can fail to alter tumor growth and transcriptional profiles in subcutaneous syngeneic mouse tumor models
por: Sheen, Allison, et al.
Publicado: (2023)

Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model
por: Piranlioglu, Raziye, et al.
Publicado: (2019)

Anti-tumor effect of aquaporin 3 monoclonal antibody on syngeneic mouse tumor model
por: Tanaka, Manami, et al.
Publicado: (2022)

Tumor Rejection by Modulation of Tumor Stromal Fibroblasts
por: Schüler, Thomas, et al.
Publicado: (2003)

Curcumin, but not Prima-1, decreased tumor cell proliferation in the syngeneic murine orthotopic bladder tumor model
por: Watanabe, Fábio T., et al.
Publicado: (2011)

Advanced non-small cell lung cancer: on relapse rechallenge the tumor, not the patient
por: Froudarakis, Marios E, et al.
Publicado: (2010)

IMMUNE AND NATURAL ANTIBODIES TO SYNGENEIC MURINE PLASMA CELL TUMORS
por: Herberman, Ronald B., et al.
Publicado: (1972)

Characterization of immune cell populations in syngeneic murine tumor models
por: Snipstad, Sofie, et al.
Publicado: (2023)

Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity
por: Schuelke, Matthew R., et al.
Publicado: (2019)

Tumor Rejection by Disturbing Tumor Stroma Cell Interactions
por: Ibe, Sabrina, et al.
Publicado: (2001)

Overexpression of Murine Rnaset2 in a Colon Syngeneic Mouse Carcinoma Model Leads to Rebalance of Intra-Tumor M1/M2 Macrophage Ratio, Activation of T Cells, Delayed Tumor Growth, and Rejection
por: De Vito, Annarosaria, et al.
Publicado: (2020)

PKHB1 Tumor Cell Lysate Induces Antitumor Immune System Stimulation and Tumor Regression in Syngeneic Mice with Tumoral T Lymphoblasts
por: Martínez-Torres, Ana Carolina, et al.
Publicado: (2019)

Participation of the H-2 antigens of tumor cells in their lysis by syngeneic T cells
Publicado: (1976)

An HNSCC syngeneic mouse model for tumor immunology research and preclinical evaluation
por: Fu, You, et al.
Publicado: (2020)

Combination of intravenously delivered cavatak (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and tumor rechallenge
por: Yuan, Min, et al.
Publicado: (2015)

Comparison of cisplatin-induced anti-tumor response in CT26 syngeneic tumors of three BALB/c substrains
por: Gong, Jeong Eun, et al.
Publicado: (2021)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

CYTOSTATIC ELIMINATION OF SYNGENEIC RAT TUMOR CELLS IN VITRO BY NONSPECIFICALLY ACTIVATED MACROPHAGES
por: Keller, R.
Publicado: (1973)

Secondary induction of cytotoxic T lymphocytes with solubilized syngeneic tumor cell plasma membranes
Publicado: (1978)

Divergent immune landscapes of primary and syngeneic Kras-driven mouse tumor models
por: Gutierrez, Wade R., et al.
Publicado: (2021)

Immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor model
por: Ghosh, Sanjana, et al.
Publicado: (2022)

Machine learning on syngeneic mouse tumor profiles to model clinical immunotherapy response
por: Zeng, Zexian, et al.
Publicado: (2022)

DNA based neoepitope vaccination induces tumor control in syngeneic mouse models
por: Viborg, Nadia, et al.
Publicado: (2023)

Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments
por: Yu, Jong W., et al.
Publicado: (2018)

Quantifying the Frequency of Tumor-propagating Cells Using Limiting Dilution Cell Transplantation in Syngeneic Zebrafish
por: Blackburn, Jessica S., et al.
Publicado: (2011)

Aryl hydrocarbon receptor acts as a tumor suppressor in a syngeneic MC38 colon carcinoma tumor model
por: Yakkundi, Poonam, et al.
Publicado: (2019)

Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment
por: Jin, Ying, et al.
Publicado: (2022)

Quantitative Imaging of Hypoxic CAIX-Positive Tumor Areas with Low Immune Cell Infiltration in Syngeneic Mouse Tumor Models
por: Boreel, Daan F., et al.
Publicado: (2023)

IMMU-01. EVALUATING THE IMPACT OF CAR DESIGN ON THE TUMOR IMMUNE MICROENVIRONMENT AND ANTI-TUMOR RESPONSE IN SYNGENEIC GLIOMA MODELS
por: Haydar, Dalia, et al.
Publicado: (2023)

Cancer neoantigens and immunogenicity: mutation position matters
por: Capietto, Aude-Hélène, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4kfgjr46h0knv7o2rjo6nk8115